bimekizumab manufacturers
- Bimekizumab
-
- $788.00
-
2026-07-13
- CAS:1418205-77-2
- Purity: 100.00%
- Supply Ability: 10g
|
| | bimekizumab Basic information |
| Product Name: | bimekizumab | | Synonyms: | bimekizumab;Research Grade Bimekizumab(DHH28803);Anti-IL-17-mAb-UCB;Anti-IL-17-monoclonal-antibody-UCB;Anti-interleukin-17-monoclonal-antibody-UCB;Research Grade Bimekizumab;Bimekizumab (anti-IL17A&IL-17F) | | CAS: | 1418205-77-2 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![bimekizumab Structure]() |
| | bimekizumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | bimekizumab Usage And Synthesis |
| Uses | Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation[1]. | | IC 50 | IL-17A; IL-17F | | References | [1] Shah M, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020 Jul;6(2):e001306. DOI:10.1136/rmdopen-2020-001306 |
| | bimekizumab Preparation Products And Raw materials |
|